December 2022
-
12.20.2022 Medicines U.S. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™ -
12.13.2022 Covid-19 Medicines Partnerships Pfizer to Provide U.S. Government with an Additional 3.7 Million Treatment Courses of PAXLOVID™ to Help Combat COVID-19 -
12.09.2022 Research Vaccines Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
November 2022
-
11.23.2022 Covid-19 Medicines Pfizer Signs Agreement to Provide the European Union with PAXLOVID™ -
11.16.2022 Covid-19 Research Vaccines Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection -
11.03.2022 Covid-19 Research Vaccines Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19
October 2022
-
10.28.2022 Medicines Safety Recommendation on Janus kinase (JAK) Inhibitors Issued in the European Union -
10.20.2022 Vaccines Advisory Committee on Immunization Practices Recommends Pfizer’s PREVNAR 20® for Adults Previously Vaccinated with PREVNAR 13® -
10.19.2022 Covid-19 Vaccines Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union -
10.17.2022 Finance Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review RSV Data Presented at ID Week 2022